PD-1 inhibitor

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial

Kim HR, Oliva M, Salas S, Wong DJ, Even C, Kim JW, Kang M, Wu SY, Lauche O, Ahn MJ, Yang MH, Lien MY, Metcalf[...]

By afschroeder • June 5, 2026

Scarring alopecia as an unexpected consequence of immune checkpoint inhibition

Kokikian N, Tarabay J, Goh C. Scarring alopecia as an unexpected consequence of immune checkpoint inhibition. JAAD Case Rep. 2025 May 8;61:1-6. doi: 10.1016/j.jdcr.2025.04.007. PMID:[...]

By afschroeder • June 18, 2025